SecBot SecBot
8-K ·Filed Apr 6, 2026

BIIB

BIOGEN INC.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0000875045-26-000039
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor Biogen's upcoming full earnings release for confirmation of the $34 million charge and any additional financial details. The preliminary nature of this filing means final results could differ.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$172.25
T+0 close · Apr 6, 2026 · via day close
Latest settled
+21.77%
T+60 · $209.74
Vs SPY
+8.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $172.25entry
  2. T+1 · 7mo ago +1.95%α +1.89% · $175.61
  3. T+5 · 7mo ago +2.03%α −2.11% · $175.74
  4. T+20 · 7mo ago +8.33%α −0.65% · $186.60
  5. T+60 · 5mo ago +21.77%α +8.59% · $209.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Biogen issued a preliminary earnings update for Q1 2026, expecting a $34 million charge for acquired in-process R&D and milestone expenses, impacting EPS by approximately $0.19 per share. This is a forward-looking estimate ahead of final results.

Key Facts

  • Biogen expects a $34 million pre-tax charge for acquired in-process R&D, upfront, and milestone expenses in Q1 2026.
  • The charge is expected to reduce both GAAP and non-GAAP diluted EPS by approximately $0.19 per share.
  • Final results for Q1 2026 are not yet finalized and remain subject to closing procedures.

Financial Impact

Approximately $34 million pre-tax charge, reducing EPS by $0.19 per share

epsdiluted_eps

Risk Factors

  • Final financial results may differ from these preliminary estimates.
  • The R&D charge could be larger or smaller than expected based on final accounting.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
47% bullish (43 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000875045-26-000039
Document: 0000875045-26-000039-index-headers.html0000875045-26-000039
Document: 0000875045-26-000039-index.html0000875045-26-000039
Document: 0000875045-26-000039.txt0000875045-26-000039
8-K Data (Synthetic)0000875045-26-000039

Track record

34 reports on BIIB

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026